Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Plebanski

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
The American Journal of Tropical Medicine and Hygiene|July 10, 2001
Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalenceE A Lee, K L Flanagan, K Odhiambo, et al.
European Journal of Immunology|December 23, 1998
Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human useM Plebanski, S C Gilbert, J Schneider, et al.
Infection and Immunity|February 21, 2002
Naturally exposed populations differ in their T1 and T2 responses to the circumsporozoite protein of Plasmodium falciparumW H H Reece, M Plebanski, P Akinwunmi, et al.
European Journal of Immunology|August 1, 1996
Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunizationC E Allsopp, M Plebanski, S Gilbert, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 10, 2001
Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assaysK L Flanagan, E A Lee, M B Gravenor, et al.
Developments in Biologicals|November 21, 2001
DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategyA V Hill, W Reece, P Gothard, et al.
Clinical and Experimental Immunology|January 24, 2004
Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The GambiaM Pinder, W H H Reece, M Plebanski, et al.
The Journal of Infectious Diseases|October 9, 1999
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccineA Lalvani, P Moris, G Voss, et al.
Trials|March 19, 2023
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)C McLeod, J Ramsay, K L Flanagan, et al.
The Journal of Infection|September 28, 2024
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years oldC McLeod, M Dymock, K L Flanagan, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The American Journal of Tropical Medicine and Hygiene|July 10, 2001
Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalenceE A Lee, K L Flanagan, K Odhiambo, et al.
European Journal of Immunology|December 23, 1998
Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human useM Plebanski, S C Gilbert, J Schneider, et al.
Infection and Immunity|February 21, 2002
Naturally exposed populations differ in their T1 and T2 responses to the circumsporozoite protein of Plasmodium falciparumW H H Reece, M Plebanski, P Akinwunmi, et al.
European Journal of Immunology|August 1, 1996
Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunizationC E Allsopp, M Plebanski, S Gilbert, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 10, 2001
Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assaysK L Flanagan, E A Lee, M B Gravenor, et al.
Developments in Biologicals|November 21, 2001
DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategyA V Hill, W Reece, P Gothard, et al.
Clinical and Experimental Immunology|January 24, 2004
Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The GambiaM Pinder, W H H Reece, M Plebanski, et al.
The Journal of Infectious Diseases|October 9, 1999
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccineA Lalvani, P Moris, G Voss, et al.
Trials|March 19, 2023
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)C McLeod, J Ramsay, K L Flanagan, et al.
The Journal of Infection|September 28, 2024
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years oldC McLeod, M Dymock, K L Flanagan, et al.
Pageof 5